- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01431937
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers (P1A114347)
5 juli 2017 bijgewerkt door: GlaxoSmithKline
A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682.
The study will also provide further evidence of the potential therapeutic dose-range by measuring the inhibitory effect of GSK2018682 on Absolute Lymphocyte Counts (ALC).
Studie Overzicht
Toestand
Voltooid
Interventie / Behandeling
Gedetailleerde beschrijving
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682.
The study will also provide further evidence of the potential therapeutic dose-range by measuring the inhibitory effect of GSK2018682 on Absolute Lymphocyte Counts (ALC).
Studietype
Ingrijpend
Inschrijving (Werkelijk)
40
Fase
- Fase 1
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
New South Wales
-
Randwick, New South Wales, Australië, 2031
- GSK Investigational Site
-
-
South Australia
-
Adelaide, South Australia, Australië, 5000
- GSK Investigational Site
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- GSK Investigational Site
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 55 jaar (Volwassen)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- Females must be of non-childbearing potential.
- BMI within the range 19 - 29 kg/m2 (inclusive).
Exclusion Criteria:
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen.
- A positive test for HIV antibody.
- History of regular alcohol consumption within 6 months of the study.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Were participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Other exclusion criteria to be detailed at the time of physical screening by the Investigator
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: GSK2018682
Active Drug
|
Active Drug
|
Placebo-vergelijker: Placebo Control
Placebo
|
Placebo
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
To investigate the safety and tolerability of repeat oral doses of GSK2018682 in healthy volunteers (males and females of non-childbearing potential)
Tijdsspanne: Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
Adverse event monitoring, Laboratory parameters (haematology, clinical chemistry, urinalysis), Ophthalmic examination
|
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
To investigate effects of repeat oral doses of GSK2018682 on heart rate and blood pressure in healthy volunteers
Tijdsspanne: Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
12-lead ECG, Telemetry ECG, Holter ECG, Vital signs (systolic and diastolic blood pressure, heart rate, respiratory rate, body temperature), Ambulatory blood pressure monitoring
|
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
To investigate effects of repeat oral doses of GSK2018682 on lung function in healthy volunteers
Tijdsspanne: Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
FEV1 obtained via spirometry
|
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
To investigate the pharmacokinetics of repeat oral doses of GSK2018682 in healthy volunteers
Tijdsspanne: Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
Peak blood concentration, Time of peak blood concentration, Area under the blood concentration-time curve over the 24-hour dose interval and area under the blood concentration-time curve from time-zero extrapolated to infinite time, Accumulation ratio, Terminal half-life, Apparent oral clearance, Through concentration
|
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
To characterize the metabolism of GSK2018682
Tijdsspanne: Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
GSK2018682 bile metabolites, GSK2018682 whole blood metabolites
|
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
Evaluate the effect of repeat oral doses of GSK2018682 on lymphocytes in healthy volunteers
Tijdsspanne: Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
% Change from baseline in absolute lymphocyte counts (ALC), % Change from baseline in subsets CD3+ [CD4+ and CD8+], CD19+, CD16+/CD56+ counts, % Change from baseline in further defined functional T cell subsets (naïve, central memory, effector memory and regulatory T cells)
|
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
To explore the PK/PD relationship between blood concentrations and changes in vital signs and ECG parameters
Tijdsspanne: Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
PK/PD model with parameters of the models will be determined that best describe the relationship between blood concentrations of GSK2018682 and vital signs and ECG parameters
|
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
To explore the PK/PD relationship between blood concentrations of GSK2018682 and reduction in lymphocyte counts
Tijdsspanne: Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
PK/PD model with parameters of the models will be determined that best describe the relationship between blood concentrations of GSK2018682 and reduction ALC and subset counts CD3+ [CD4+ and CD8+], CD19+, CD16+/CD56+ and further defined functional T cell subsets (naïve, central memory, effector memory and regulatory T cells)
|
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
10 oktober 2010
Primaire voltooiing (Werkelijk)
29 maart 2011
Studie voltooiing (Werkelijk)
29 maart 2011
Studieregistratiedata
Eerst ingediend
11 augustus 2011
Eerst ingediend dat voldeed aan de QC-criteria
8 september 2011
Eerst geplaatst (Schatting)
12 september 2011
Updates van studierecords
Laatste update geplaatst (Werkelijk)
7 juli 2017
Laatste update ingediend die voldeed aan QC-criteria
5 juli 2017
Laatst geverifieerd
1 juli 2017
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 114347
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
JA
Beschrijving IPD-plan
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Bestudeer gegevens/documenten
-
Gegevensset individuele deelnemers
Informatie-ID: 114347Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Geannoteerd casusrapportformulier
Informatie-ID: 114347Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulier geïnformeerde toestemming
Informatie-ID: 114347Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Leerprotocool
Informatie-ID: 114347Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisch analyseplan
Informatie-ID: 114347Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisch onderzoeksrapport
Informatie-ID: 114347Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Specificatie gegevensset
Informatie-ID: 114347Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Placebo
-
SamA Pharmaceutical Co., LtdOnbekendAcute bronchitis | Acute bovenste luchtweginfectieKorea, republiek van
-
National Institute on Drug Abuse (NIDA)VoltooidCannabisgebruikVerenigde Staten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyVoltooidMannelijke proefpersonen met diabetes type II (T2DM)Duitsland
-
Heptares Therapeutics LimitedVoltooidFarmacokinetiek | Veiligheid problemenVerenigd Koninkrijk
-
Texas A&M UniversityNutraboltVoltooidGlucose and Insulin Response
-
ItalfarmacoVoltooidBecker spierdystrofieNederland, Italië
-
Longeveron Inc.BeëindigdHypoplastisch linkerhartsyndroomVerenigde Staten
-
Soroka University Medical CenterVoltooid
-
Regado Biosciences, Inc.VoltooidGezonde vrijwilligerVerenigde Staten